Adaptimmune Therapeutics plc

Ladies and gentlemen, thank you for standing by and welcome to Adapt-Immune's third quarter 2020 financial results and business update. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question and answer session. To ask a question during the session, you will need to press star one on your telephone. Please be advised that today's conference may be recorded. If you require any further assistance, please press star zero. I would now like to hand the conference over to your host, Adapt-Immune's investor relations, Julie Miller. Madam, please go ahead.

Good morning, and welcome to ADAPT Immune's conference call to discuss our third quarter 2020 financial results and business updates. I would ask you to please review the full text of our forward-looking statements from this morning's press release. We anticipate making projections during this call, and actual results could differ materially due to a number of factors, including those outlined in our latest filings with the SEC. Adrian Rockliffe, our chief executive officer, and Elliot Norrie, our chief medical officer, are with me for the prepared portion of this call. Other members of our management team will be available for Q&A. With that, I'll turn the call over to Adrian Rockliffe.

Thank you, Julie, and thank you, everyone, for joining us. Before Elliot talks about the clinical updates we'll be providing later this month at CITSE and CTOS, I want to share a few reflections. This time last year, I hosted my first quarterly call as CEO, and I said then that I was committed to our focus on execution, and this remains our focus. While the management of the pandemic continues to evolve at our clinical sites, I'm happy to report that we've seen an increase in enrollment across our early phase clinical trials over the course of the third quarter. We are enrolling and treating patients in the ADPA2 AFP trial in HCC and and our ADPA2M4CD8 next-generation surpassed trial in a range of solid tumors. The numbers of patients that we see coming in for apheresis and cell manufacturing prior to being treated continue to provide us with confidence that we will be able to evaluate the initial safety and efficacy of these products in the coming months. As I reported last call, our Phase II Spearhead 1 trial with ADPA2M4 in sarcoma has been less affected by COVID-19. Recruitment continues to go very well, and we're on track to complete enrollment in the first half of 2021, further strengthening our ambition to launch ADPA2M4 in the U.S. in 2022. I want to thank the investigators, study coordinators, and other healthcare professionals at the centers where we conduct our clinical trials, and everyone working in our clinical, CMC, and supply teams for their work and commitment Later this month, we will have our virtual investor day, where I will lay out the strategy and value drivers for the company over the next five years. We will present our perspective on the blockbuster market opportunity that May J4 targeted products represent, our near-term plans for bringing ADPA2M4 to market in 2022, and the cell therapy products we are developing beyond our current clinical autologous pipelines. You will also hear from senior leaders who will provide more details about how we will deliver our vision for the future of the company. There will be no new data updates. As we've said previously, we will provide new clinical data when we believe we have ample information to determine next steps, and these communications will be at medical congresses. I will now turn it over to Elliot to provide more perspective on our upcoming presentations at CITSE and CITOS. Elliot, over to you.